Clinical Trials Browser

INDUSTRY × Has announcements × Dexamethasone × Clear all

NCT05083169 2026-04-13

MajesTEC-3

Phase 3 Active not recruiting

587 enrolled 2 FDA

Multiple Myeloma

NCT03652064 2026-04-08

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Phase 3 Active not recruiting

395 enrolled 11 charts 3 FDA

Multiple Myeloma

NCT03275285 2026-02-09

IKEMA

Phase 3 Completed

302 enrolled 38 charts 2 FDA

Multiple Myeloma

NCT03201965 2025-11-26

A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

Phase 3 Completed

416 enrolled 28 charts 5 FDA

Amyloidosis

NCT03589326 2025-11-26

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Phase 3 Active not recruiting

245 enrolled 15 charts 2 FDA

LymphoidOther hematologic neoplasm

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

NCT02252172 2025-10-20

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

Phase 3 Completed

737 enrolled 30 charts 2 FDA

Multiple Myeloma

NCT03158688 2025-05-09

CANDOR

Phase 3 Completed

466 enrolled 33 charts 3 FDA

Multiple Myeloma

NCT03412565 2025-04-29

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

Phase 2 Completed

265 enrolled 21 charts 5 FDA

Multiple Myeloma

NCT01998971 2025-04-25

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Phase 1 Completed

240 enrolled 3 FDA

Multiple Myeloma

NCT02990338 2025-01-17

ICARIA-MM

Phase 3 Completed

307 enrolled 32 charts 3 FDA

Multiple Myeloma

NCT03319667 2024-11-27

IMROZ

Phase 3 Active not recruiting

475 enrolled 3 FDA

Multiple Myeloma

NCT04246047 2024-10-24

DREAMM 7

Phase 3 Active not recruiting

494 enrolled 10 charts 3 FDA

Multiple Myeloma

NCT02578680 2024-09-20

MK-3475-189

Phase 3 Completed

616 enrolled 19 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT03110562 2024-08-21

BOSTON

Phase 3 Completed

402 enrolled 22 charts 3 FDA

Multiple Myeloma, Recurrence

NCT02393859 2024-05-29

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Phase 3 Completed

111 enrolled 23 charts 2 FDA

LymphoidOther hematologic neoplasm

Immunoproliferative Disorders, Lymphoproliferative Disorders, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02336815 2023-01-26

STORM

Phase 2 Completed

202 enrolled 30 charts 2 FDA

NCT02963493 2022-11-22

HORIZON

Phase 2 Completed

157 enrolled 26 charts 2 FDA

Multiple Myeloma